- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06951685
Xeltis perifer artärsjukdom (XPAD) förbikopplingsledning Tidig genomförbarhetsstudie
Prospektiv, icke-randomiserad, tidig genomförbarhet klinisk studie för att bedöma genomförbarheten av den nya Xeltis perifera artärsjukdom (XPAD) förbikopplingsledning
A prospective, single arm, non-randomized early feasibility study to evaluate the preliminary safety and performance of the XPAD conduit in patients with peripheral arterial occlusive disease (PAOD), scheduled to undergo elective above-knee femoral popliteal bypass surgery.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
San José, Costa Rica
- Centro de Investigación y Manejo del Cáncer (CIMCA)
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Subjects with femoral artery occlusion who require elective above-knee femoral popliteal bypass surgery
- Patient has Rutherford grade 3, 4, or 5 occlusive vascular disease and TASC C or D lesions. Rutherford grade 5 may be included with a wound, ischemia and foot infection (WiFi) classification of up to grade 2, provided there are two outflow vessels with at least one reaching the pedal arch
- At least 18 years of age at screening
- Suitable anatomy (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline)
- Patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
- Patient has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography
- Life expectancy of at least 24 months
Exclusion Criteria:
- Subject requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure.
- Presence or history of bypass in the diseased limb
- Subject requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts
- Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above)
- History of acute arterial occlusion requiring an emergent intervention
- Severe chronic renal insufficiency (serum creatinine >2.5 mg/dL) or undergoing hemodialysis
- Previous renal transplant
- Uncontrolled arterial hypertension (BP >200 mmHg) at 2 successive readings
- Uncontrolled or poorly controlled diabetes
- Abnormal blood values that could influence patient recovery and or/ graft hemostasis
- Reduced liver function, defined as: >2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) >1.5 or prothrombin time (PT) >18 seconds
- Any active local or systemic infection
- Known heparin-induced thrombocytopenia
- Known active bleeding disorder and/or any coagulopathy or thromboembolic disease
- Allergies to study device (nitinol) or agents/medication, such as contrast agents or aspirin, that can't be controlled medically
- Previous enrolment in this study
- Subject is participating in another study
- Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives
- Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit
Intra-operative exclusion criteria:
1. Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: XPAD -förbikopplingsledning
|
The XPAD bypass conduit is a sterile, restorative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 33cm length and 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The XPAD conduit is in a straight configuration and may be implanted above the knee for elective femoral popliteal bypass surgery. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Frihet från enhetsrelaterad SAE
Tidsram: Dag 1, 1, 6 och 12 månader
|
Dag 1, 1, 6 och 12 månader
|
|
|
Primary patency rate
Tidsram: 12 months
|
Primary patency: Defined as the interval between graft implantation and the first intervention to maintain or restore patency |
12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Frihet från enhetsrelaterad SAE
Tidsram: 24 och 36 månader
|
24 och 36 månader
|
|
|
Hastighet av sår/transplantatinfektioner
Tidsram: 1, 6, 12, 24 och 36 månader
|
1, 6, 12, 24 och 36 månader
|
|
|
Frihet från dödligheten
Tidsram: 1, 6, 12, 24 och 36 månader
|
1, 6, 12, 24 och 36 månader
|
|
|
Implantation success rate
Tidsram: Day 1
|
Implantation success: Defined as a technically successful XPAD conduit implantation in the planned configuration, free from kinking and tension in the anastomoses, and a patent XPAD conduit at the moment of discharge |
Day 1
|
|
Freedom from Major Bleeding events
Tidsram: Day 1, 1 and 6 months
|
Major Bleeding: Defined as type 3, 4 or 5 bleeding according to the Bleeding Academic Research Consortium (BARC) classifications |
Day 1, 1 and 6 months
|
|
Patency (primary, primary assisted, and secondary) rates
Tidsram: 6, 12, 24, and 36 months
|
Primary patency: Defined as the interval between graft implantation and the first intervention to maintain or restore patency. Assisted primary patency: Defined as the interval between graft implantation and the first occlusion (thrombosis), including interventions (operative or endovascular) aimed to maintain the functionality the graft. Secondary patency: Defined as the interval between graft implantation and abandonment with or without interventions (operative or endovascular) aimed to maintain the functionality the graft, including occurrence of a censored event (death, change of modality, loss of follow-up) |
6, 12, 24, and 36 months
|
|
Freedom from Major Amputations
Tidsram: 1, 6, 12, 24, and 36 months
|
Major Amputation: Defined as any amputation that results in limb shortening |
1, 6, 12, 24, and 36 months
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- XEL-CR-15
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .